Novartis Receives EU Approval for Juvenile Arthritis Treatment - - BioPharm International

ADVERTISEMENT

Novartis Receives EU Approval for Juvenile Arthritis Treatment


The European Commission (EC) has approved the use of Ilaris (canakinumab) in the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids, Novartis announced in a press release. SJIA is a rare and disabling form of childhood arthritis with limited treatment options. The condition is characterized by spiking fever, rash, and arthritis that can affect children as young as 2 years old and can continue into adulthood, the press release explained. Ilaris can be given as monotherapy or in combination with methotrexate.

Ilaris is a selective, fully human, monoclonal antibody that inhibits interleukin-1 (IL-1) beta, which is an important part of the body's immune system defenses. Excessive production of IL-1 beta plays a prominent role in certain inflammatory diseases. Ilaris neutralizes IL-1 beta for a sustained period of time, therefore inhibiting inflammation. Ilaris is approved for the treatment of SJIA in the US, for the symptomatic treatment of refractory acute gouty arthritis in the EU, and for treatment of cryopyrin-associated periodic syndromes (CAPS) in more than 60 countries.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Works to Speed Up Ebola Treatment
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
Harnessing the Power of Modified T Cells to Treat Cancer
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
Author Guidelines

Click here